A comparison of patient survival and tumour growth kinetics in human bronchogenic carcinoma

Br J Cancer. 1988 Oct;58(4):419-22. doi: 10.1038/bjc.1988.233.

Abstract

A series of 46 primary bronchogenic carcinomas for which thymidine labelling index (%TLI) (in all cases) and tumour doubling time (DTact) (in 13 cases) had previously been measured were followed up for 5 years and these data compared with length of post operative survival, tumour volume at operation and pathological staging. We found no correlation between reduced survival and higher tumour %TLI, indeed the reverse may be true. Larger tumours tended to have higher labelling indices considering either primary tumour volume or 'T'-category. Five year survivors had smaller tumours, tended to have T1 tumours and Stage I disease but did not have significantly lower tumour %TLIs. No relationship was found between DTact and any other parameter.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenocarcinoma / pathology
  • Carcinoma, Bronchogenic / mortality
  • Carcinoma, Bronchogenic / pathology*
  • Carcinoma, Small Cell / pathology
  • Carcinoma, Squamous Cell / pathology
  • Cell Division
  • Humans
  • Lung Neoplasms / mortality
  • Lung Neoplasms / pathology*
  • Mitosis
  • Neoplasm Staging
  • Thymidine / metabolism
  • Time Factors

Substances

  • Thymidine